Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BVX.L Stock Summary
Top 10 Correlated ETFs
BVX.L
In the News
BVX.L Financial details
Company Rating
Neutral
Market Cap
9.49M
Income
-
Revenue
-
Book val./share
0.04
Cash/share
0.03
Dividend
-
Dividend %
-
Employees
17
Optionable
No
Shortable
Yes
Earnings
28 Mar 2024
P/E
-3.04
Forward P/E
-
PEG
-
P/S
-
P/B
1.92
P/C
375
P/FCF
-3.41
Quick Ratio
8.41
Current Ratio
10.14
Debt / Equity
0.07
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-37.21%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
1.14%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-7.69%
Inst Own
-
Inst Trans
-
ROA
-55%
ROE
-49%
ROC
-0.72%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
86.19M
Shs Float
57.47M
-
-
-
-
Target Price
-
52W Range
0.1105-16.0
52W High
-
52W Low
-
RSI
15
Rel Volume
0.42
Avg Volume
34.9K
Volume
14.57K
Perf Week
-4.26%
Perf Month
-2.17%
Perf Quarter
-10%
Perf Half Y
-19.64%
-
-
-
-
Beta
-0.604
-
-
Volatility
0.25%, 0.17%
Prev Close
0%
Price
11.25
Change
-2.6%
BVX.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.01 | -0.01 | -0.01 | -0.06 | -0.04 | |
Operating cash flow per share | -0.01 | -0.01 | 0 | -0.05 | -0.04 | |
Free cash flow per share | -0.01 | -0.01 | 0 | -0.05 | -0.04 | |
Cash per share | 0 | 0 | 0.11 | 0.16 | 0.05 | |
Book value per share | 0 | 0 | 0.11 | 0.16 | 0.06 | |
Tangible book value per share | 0 | 0 | 0.11 | 0.16 | 0.06 | |
Share holders equity per share | 0 | 0 | 0.11 | 0.16 | 0.06 | |
Interest debt per share | 0 | 0 | 0.01 | 0.02 | 0 | |
Market cap | 16.86M | 16.86M | 16.86M | 11.47M | 11.24M | |
Enterprise value | 16.65M | 16.73M | 10M | 5.65M | 8.25M | |
P/E ratio | -44.6 | -41.22 | -39.67 | -4.9 | -4.5 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -34.83 | -47.23 | -101.56 | -6.42 | -4.69 | |
PFCF ratio | -34.83 | -47.23 | -73.62 | -6.26 | -4.03 | |
P/B Ratio | 54.39 | 93.66 | 2.28 | 1.81 | 2.84 | |
PTB ratio | 54.39 | 93.66 | 2.28 | 1.81 | 2.84 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -34.68 | -31.81 | -19.23 | -3.88 | -2.92 | |
EV to operating cash flow | -34.4 | -46.86 | -60.24 | -3.16 | -3.44 | |
EV to free cash flow | -34.4 | -46.86 | -43.67 | -3.08 | -2.96 | |
Earnings yield | -0.02 | -0.02 | -0.03 | -0.2 | -0.22 | |
Free cash flow yield | -0.03 | -0.02 | -0.01 | -0.16 | -0.25 | |
Debt to equity | 0 | 0 | 0.09 | 0.04 | 0.07 | |
Debt to assets | 0 | 0 | 0.09 | 0.04 | 0.07 | |
Net debt to EBITDA | 0.44 | 0.25 | 13.19 | 4 | 1.06 | |
Current ratio | 9.13 | 3.08 | 23.25 | 17.26 | 10.14 | |
Interest coverage | 0 | 0 | -25.79 | -2.95 | 743.75 | |
Income quality | 1.01 | 0.68 | 0.34 | 0.7 | 0.81 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.38 | 0.03 | 0.16 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | -63 | -1 | -2.58 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.02 | 0.02 | 0.13 | 0.47 | 0.23 | |
ROIC | -1.22 | -2.27 | -0.05 | -0.26 | -0.55 | |
Return on tangible assets | -1.09 | -1.54 | -0.05 | -0.34 | -0.55 | |
Graham Net | 0 | 0 | 0.11 | 0.15 | 0.05 | |
Working capital | 309K | 179K | 7.34M | 6.16M | 3.57M | |
Tangible asset value | 310K | 180K | 7.41M | 6.33M | 3.96M | |
Net current asset value | 309K | 179K | 7.34M | 5.99M | 3.39M | |
Invested capital | 0 | 0 | 0.09 | 0.04 | 0.07 | |
Average receivables | 0 | 0 | 68K | 198K | 412.5K | |
Average payables | 0 | 22.5K | 144K | 166K | 90.5K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 96K | 547.5 | 270.73 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0.67 | 1.35 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.22 | -2.27 | -0.06 | -0.37 | -0.63 | |
Capex per share | 0 | 0 | 0 | 0 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0 | 0 | 0 | -0.02 | -0.02 | |
Operating cash flow per share | 0 | 0 | 0 | -0.02 | -0.02 | |
Free cash flow per share | 0 | 0 | 0 | -0.02 | -0.02 | |
Cash per share | 0 | 0 | 0 | 0.05 | 0.03 | |
Book value per share | 0 | 0 | 0 | 0.06 | 0.04 | |
Tangible book value per share | 0 | 0 | 0 | 0.06 | 0.04 | |
Share holders equity per share | 0 | 0 | 0 | 0.06 | 0.04 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 0 | 0 | 0 | 11.24M | 9.92M | |
Enterprise value | -376K | -5.82M | -4.3M | 8.25M | 8.21M | |
P/E ratio | 0 | 0 | 0 | -2.43 | -2.12 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | 0 | 0 | 0 | -10.45 | -8.11 | |
PFCF ratio | 0 | 0 | 0 | -8.84 | -7.17 | |
P/B Ratio | 0 | 0 | 0 | 2.84 | 3.5 | |
PTB ratio | 0 | 0 | 0 | 2.84 | 3.5 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0 | 0 | 0 | -6.36 | -6.25 | |
EV to operating cash flow | 0 | 0 | 0 | -7.67 | -6.71 | |
EV to free cash flow | 0 | 0 | 0 | -6.49 | -5.94 | |
Earnings yield | 0 | 0 | 0 | -0.1 | -0.12 | |
Free cash flow yield | 0 | 0 | 0 | -0.11 | -0.14 | |
Debt to equity | 0 | 0.04 | 0.05 | 0.07 | 0.07 | |
Debt to assets | 0 | 0.04 | 0.04 | 0.07 | 0.06 | |
Net debt to EBITDA | 0 | 0 | 0 | 2.31 | 1.3 | |
Current ratio | 1.69 | 17.26 | 7.49 | 10.14 | 6.85 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0 | 0 | 0 | 0.93 | 1.04 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0.18 | 0.13 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | -1.52 | -2.11 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 0 | 0 | 0.15 | 0.13 | |
ROIC | 0 | 0 | 0 | -0.26 | -0.36 | |
Return on tangible assets | 0 | 0 | 0 | -0.26 | -0.34 | |
Graham Net | 0 | 0 | 0 | 0.05 | 0.03 | |
Working capital | 234K | 6.16M | 4.54M | 3.57M | 2.39M | |
Tangible asset value | -348K | 6.33M | 5.05M | 3.96M | 2.83M | |
Net current asset value | -435K | 5.99M | 4.54M | 3.39M | 2.18M | |
Invested capital | 0 | 0.04 | 0.05 | 0.07 | 0.07 | |
Average receivables | 0 | 0 | 0 | 282.5K | 731.5K | |
Average payables | 301K | 204K | 261.5K | 283K | 163K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 78.75 | 253.42 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 1.14 | 0.36 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0 | 0 | 0 | -0.29 | -0.41 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
BVX.L Frequently Asked Questions
What is BiVictriX Therapeutics Plc stock symbol ?
BiVictriX Therapeutics Plc is a GB stock and trading under the symbol BVX.L
What is BiVictriX Therapeutics Plc stock quote today ?
BiVictriX Therapeutics Plc stock price is $11.25 today.
Is BiVictriX Therapeutics Plc stock public?
Yes, BiVictriX Therapeutics Plc is a publicly traded company.